MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Avelumab

CAS No. : 1537032-82-8

MCE 国际站：Avelumab

产品活性：Avelumab 是一个人 IgG1 抗 PD-L1 单克隆抗体，具有潜在的抗体依赖性细胞介导的细胞毒性作用。

研究领域：Immunology/Inflammation

作用靶点：PD-1/PD-L1

In Vitro: Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold (P=0.01) in JHC7 cells relative to isotype control. When the cells are treated with IFN-γ, Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold; P=0.001), UM-Chor1 (7.34-fold; P<0.001), U-CH2 (2.6 fold; P=0.008), MUG-Chor1 (8.38-fold; P=0.0016). Avelumab effectively increases antibody-dependent cell-mediated cytotoxicity (ADCC) of both the non-cancer stem cell (CSC) and CSC subpopulations to the same degree. Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8⁺ T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs).

In Vivo: Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant (P<0.01) reduction in the average tumor volume of the Avelumab-treated mice. Reduction in MB49 tumor growth in the mice treated with Avelumab is durable and leads to a significant (P<0.05) improvement in percent survival. Avelumab treatment of 10 mice with bladder tumors results in complete tumor regression in 8 mice, confirmed by histopathology. However, in mice depleted of either CD4 or CD8 cells, Avelumab treatment is much less effective in controlling bladder tumor burden with tumor breakthrough occurring in a higher frequency in mice depleted of CD4 T cells.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Rulonilimab  |  PD-1/PD-L1-IN-19  |  [D-Leu-4]-OB3  |  NSC622608  |  Sulindac  |  BMS-1166  |  PD-1/PD-L1-IN-18  |  Pacmilimab  |  Anti-Mouse PD-L1 Antibody  |  Vudalimab  |  PD-1/PD-L1-IN-24  |  Cetrelimab  |  Human PD-L1 inhibitor III  |  PD-1/PD-L1-IN-20  |  PD-1-IN-20  |  PD-1/PD-L1-IN 5  |  Sintilimab  |  PD-1/PD-L1-IN-9 hydrochloride  |  Nivolumab  |  PD-1/PD-L1-IN-16  |  WL12  |  PD-1/PD-L1-IN 6  |  Acasunlimab  |  PD-1/PD-L1-IN-14  |  PD1-PDL1-IN 1  |  Sugemalimab  |  MAX-10181  |  PD-1/PD-L1-IN-23  |  D18

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。